| Income Statement | 2026-06-30 | 2025-12-31 | 2025-09-30 | |
|---|---|---|---|---|
| Research and development | 4,557,383 | 4,129,102* | 2,523,305 | |
| General and administrative | 2,638,629 | 2,518,404.5* | 2,327,391 | |
| Total operating expenses | 7,196,012 | 6,647,506.5 | 4,850,696 | |
| Loss from operations | -7,196,012 | -6,647,506.5* | -4,850,696 | |
| Loss (gain) on valuation of warrants | -132,000 | 440,104* | -294,276 | |
| Interest income | 133,359 | 134,255.5* | 112,543 | |
| Total other income (expense) | 265,359 | -305,848.5* | 406,819 | |
| Loss before income taxes | -6,930,653 | -6,953,355 | - | |
| Net loss | -6,930,653 | -6,953,355 | -4,443,877 | |
| Basic EPS | -0.57 | -2.666 | -1.41 | |
| Diluted EPS | -0.57 | -2.666 | -1.41 | |
| Basic Average Shares | 12,231,851 | 2,608,317* | 3,162,040 | |
| Diluted Average Shares | 12,231,851 | 2,608,317* | 3,162,040 | |
Cellectar Biosciences, Inc. (CLRB)
Cellectar Biosciences, Inc. (CLRB)